Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK.

Blood Adv. 2019 May 14;3(9):1540-1545. doi: 10.1182/bloodadvances.2019000090.

2.

Andreas Vesalius and De Fabrica.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 May;94(5):e67-e68. doi: 10.1016/j.mayocp.2019.03.018. No abstract available.

PMID:
31054619
3.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
4.

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.

El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA.

Leukemia. 2019 Mar 28. doi: 10.1038/s41375-019-0449-1. [Epub ahead of print]

PMID:
30923318
5.

John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Mar;94(3):e45-e46. doi: 10.1016/j.mayocp.2019.01.023. No abstract available.

PMID:
30832803
6.

Rethinking clinical trial endpoints in myelodysplastic syndromes.

Sekeres MA, Steensma DP.

Leukemia. 2019 Mar;33(3):570-575. doi: 10.1038/s41375-018-0367-7. Epub 2019 Jan 30. Review.

PMID:
30700839
7.

Georges de Bellio (1826-1894): Doctor, Friend, and Patron of the Impressionist Painters.

Dumitrascu DL, Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Jan;94(1):e7. doi: 10.1016/j.mayocp.2018.11.009. No abstract available.

PMID:
30611460
8.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):264-269. doi: 10.1182/asheducation-2018.1.264. Review.

PMID:
30504320
9.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Blood Adv. 2018 Nov 27;2(22):3404-3410. doi: 10.1182/bloodadvances.2018020222. Review.

10.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S.

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7. Review.

PMID:
30404811
11.

Herman Boerhaave - Master Clinician and Humanist.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 Nov;93(11):e119-e120. doi: 10.1016/j.mayocp.2018.09.014. No abstract available.

PMID:
30392557
12.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

PMID:
30289970
13.

An RNA bestiary in splicing-mutant MDS.

Steensma DP.

Blood. 2018 Sep 20;132(12):1217-1219. doi: 10.1182/blood-2018-07-859942. No abstract available.

PMID:
30237252
14.

Werner Forssmann: A Pioneer of Interventional Cardiology and Auto-Experimentation.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2018 Sep;93(9):e97-e98. doi: 10.1016/j.mayocp.2017.08.026. No abstract available.

PMID:
30193685
15.

How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

Steensma DP.

Blood. 2018 Oct 18;132(16):1657-1663. doi: 10.1182/blood-2018-06-860882. Epub 2018 Sep 5. Review. Erratum in: Blood. 2018 Nov 29;132(22):2419.

PMID:
30185432
16.

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.

El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, Amrein P, Stone RM, Temel JS.

Oncologist. 2019 Feb;24(2):247-254. doi: 10.1634/theoncologist.2018-0317. Epub 2018 Aug 23.

PMID:
30139841
17.

Clinical Implications of Clonal Hematopoiesis.

Steensma DP.

Mayo Clin Proc. 2018 Aug;93(8):1122-1130. doi: 10.1016/j.mayocp.2018.04.002. Epub 2018 Jul 4. Review.

PMID:
30078412
18.

Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes.

Zhang Q, Steensma DP, Yang J, Dong T, Wu MX.

Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.

PMID:
30050123
19.

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.

Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS.

BMJ Open. 2018 Jul 23;8(7):e019955. doi: 10.1136/bmjopen-2017-019955.

20.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

21.

Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes.

Brunner AM, Weng S, Cronin A, Fathi AT, Habib AR, Stone R, Graubert T, Steensma DP, Abel GA.

Am J Hematol. 2018 Sep;93(9):1119-1126. doi: 10.1002/ajh.25166. Epub 2018 Aug 28.

PMID:
30033577
22.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.

Riley LG, Heeney MM, Rudinger-Thirion J, Frugier M, Campagna DR, Zhou R, Hale GA, Hilliard LM, Kaplan JA, Kwiatkowski JL, Sieff CA, Steensma DP, Rennings AJ, Simons A, Schaap N, Roodenburg RJ, Kleefstra T, Arenillas L, Fita-Torró J, Ahmed R, Abboud M, Bechara E, Farah R, Tamminga RYJ, Bottomley SS, Sanchez M, Huls G, Swinkels DW, Christodoulou J, Fleming MD.

Haematologica. 2018 Dec;103(12):2008-2015. doi: 10.3324/haematol.2017.182659. Epub 2018 Jul 19.

23.

Henry David Thoreau's Final Journey: Minnesota.

Steensma DP, Roede CA, Kyle RA.

Mayo Clin Proc. 2018 Jul;93(7):e75-e76. doi: 10.1016/j.mayocp.2017.07.021. No abstract available.

PMID:
29976384
24.

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.

PMID:
29937400
25.

Myelodysplastic syndromes current treatment algorithm 2018.

Steensma DP.

Blood Cancer J. 2018 May 24;8(5):47. doi: 10.1038/s41408-018-0085-4. Review.

26.

Cancer research in the United States: A critical review of current status and proposal for alternative models.

Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J.

Cancer. 2018 Jul 15;124(14):2881-2889. doi: 10.1002/cncr.31522. Epub 2018 May 14. No abstract available.

PMID:
29757456
27.

Fertility preservation in women with marrow failure syndromes prior to allogeneic stem cell transplantation.

Mehm AR, Steensma DP, Srouji SS, Ginsburg ES, Brady PC.

Am J Hematol. 2018 May 13. doi: 10.1002/ajh.25130. [Epub ahead of print] No abstract available.

28.
29.

Jöns Jacob Berzelius - A Father of Chemistry.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 May;93(5):e53-e54. doi: 10.1016/j.mayocp.2017.07.020. No abstract available.

PMID:
29728209
30.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK.

Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3.

PMID:
29724895
31.

New Insights from Studies of Clonal Hematopoiesis.

Gibson CJ, Steensma DP.

Clin Cancer Res. 2018 Oct 1;24(19):4633-4642. doi: 10.1158/1078-0432.CCR-17-3044. Epub 2018 Apr 27. Review.

PMID:
29703819
32.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
33.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan8292. doi: 10.1126/scitranslmed.aan8292.

34.

Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.

Steensma DP, Ebert BL.

N Engl J Med. 2018 Mar 29;378(13):1244-1245. doi: 10.1056/NEJMe1802610. No abstract available.

PMID:
29590545
35.

Christian Albert Theodor Billroth: Founder of Abdominal Surgery.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 Mar;93(3):e29-e30. doi: 10.1016/j.mayocp.2017.06.026. No abstract available.

PMID:
29502575
36.

Prognosis in myelodysplastic syndromes: The attractions and limitations of simplicity.

Steensma DP.

Am J Hematol. 2018 May;93(5):605-606. doi: 10.1002/ajh.25068. Epub 2018 Feb 26. No abstract available.

37.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
38.

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Ghobrial IM, Detappe A, Anderson KC, Steensma DP.

Nat Rev Clin Oncol. 2018 Apr;15(4):219-233. doi: 10.1038/nrclinonc.2017.197. Epub 2018 Jan 9. Review.

PMID:
29311715
39.

Álvaro Alvim-Radiologist and Brazilian "Martyr to Science".

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2018 Jan;93(1):e7. doi: 10.1016/j.mayocp.2017.06.025. No abstract available.

PMID:
29304925
40.

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT.

Blood Adv. 2017 Oct 18;1(23):2032-2040. doi: 10.1182/bloodadvances.2017010165. eCollection 2017 Oct 24.

41.

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia.

Morgan EA, Lee MN, DeAngelo DJ, Steensma DP, Stone RM, Kuo FC, Aster JC, Gibson CJ, Lindsley RC.

Blood Adv. 2017 Sep 13;1(21):1786-1789. doi: 10.1182/bloodadvances.2017011197. eCollection 2017 Sep 26. No abstract available.

42.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G.

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. No abstract available.

43.

The Raven.

Steensma DP.

J Clin Oncol. 2018 Feb 10;36(5):512-513. doi: 10.1200/JCO.2017.76.3458. Epub 2017 Dec 13. No abstract available.

PMID:
29236583
44.

The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.

Steensma DP.

Best Pract Res Clin Haematol. 2017 Dec;30(4):295-300. doi: 10.1016/j.beha.2017.09.009. Epub 2017 Sep 22. Review.

PMID:
29156198
45.

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK.

Am J Hematol. 2018 Feb;93(2):254-261. doi: 10.1002/ajh.24968. Epub 2017 Nov 21.

46.

Thalassemia and Thomas Benton Cooley.

Siddiqui S, Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Nov;92(11):e161-e162. doi: 10.1016/j.mayocp.2017.06.024. Epub 2017 Nov 1. No abstract available.

PMID:
29101943
47.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

48.

Charles Fletcher, The Centaur Company, and Proprietary Medicine Revenue Stamps.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Sep;92(9):e127-e128. doi: 10.1016/j.mayocp.2017.06.021. No abstract available.

PMID:
28870369
49.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G.

Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

50.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

Supplemental Content

Loading ...
Support Center